Antimicrobial susceptibility patterns of unusual nonfermentative gram-negative bacilli isolated from Latin America: Report from the SENTRY Antimicrobial Surveillance Program (1997-2002)

Memorias do Instituto Oswaldo Cruz

Volumn 100, Issue 6, 2005, Pages 571-577

  Gales, Ana C ^a   Jones, Ronald N ^b   Andrade, Soraya S ^a   Sader, Helio S ^b  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b JMI LABORATORIES   (United States)

Author keywords

Antimicrobial susceptibility; Latin America; Nonfermentative gram negative; SENTRY

Indexed keywords

ACHROMOBACTER; ALCALIGENES; BACILLI; BURKHOLDERIA; BURKHOLDERIA CEPACIA; NEGIBACTERIA; RALSTONIA; RALSTONIA PICKETTII;

EID: 27744533884     PISSN: 00740276     EISSN: 16788060     Source Type: Journal    
DOI: 10.1590/S0074-02762005000600011     Document Type: Article

References (36)

1. Bellais S, Poirel L, Leotard S, Naas T, Nordmann P 2000. Genetic diversity of carbapenem-hydrolyzing metallo-beta-lactamases from Chryseobacterium (Flavobacterium) indologenes. Antimicrob Agents Chemother 44: 3028-3034.
2. Beringer PM, Appleman MD 2000. Unusual respiratory bacterial flora in cystic fibrosis: microbiologic and clinical features. Curr Opin Pulm Med 6: 545-550.
3. Biedenbach DJ, Croco MA, Barrett TJ, Jones RN 1999. Comparative in vitro activity of gatifloxacin against Stenotrophomonas maltophilia and Burkholderia species isolates including evaluation of disk diffusion and E test methods. Eur J Clin Microbiol Infect Dis 18: 428-431.
4. Bizet C, Tekaia F, Philippon A 1993. In-vitro susceptibility of Alcaligenes faecalis compared with those of other Alcaligenes spp. to antimicrobial agents including seven beta-lactams. J Antimicrob Chemother 32: 907-910.
5. Bloch KC, Nadarajah R, Jacobs R 1997. Chryseobacterium meningosepticum: an emerging pathogen among immunocompromised adults. Medicine 76: 30-41.
6. Bonacorsi S, Fitoussi F, Lhopital S, Bingen E 1999. Comparative in vitro activities of meropenem, imipenem, temocillin, piperacillin, and ceftazidime in combination with tobramycin, rifampin or ciprofloxacin against Burkholderia cepacia isolates from patients with cystic fibrosis. Antimicrob Agents Chemother 43: 213-217.
7. Dawis MA, Isenberg HD, France KA, Jenkins SG 2003. In vitro activity of gatifloxacin alone and in combination with cefepime, meropenem, piperacillin and gentamicin against multidrug-resistant organisms J Antimicrob Chemother 51: 1203-211.
8. Detsika MG, Corkill JE, Magalhães M, Glendinning KJ, Hart CA, Winstanley C 2003. Molecular typing of, and distribution of genetic markers among Burkholderia cepacia complex isolates from Brazil. J Clin Microbiol 41: 4148-4153.
9. Duggan JM, Goldstein SJ, Chenoweth CE, Kauffman CA, Bradley SF 1996. Achromobacter xylosoxidans bacteremia: report of four cases and review of the literature. Clin Infect Dis 23: 569-576.
10. Dunne WM, Maisch S 1995. Epidemiological investigation of infections due to Alcaligenes species in children and patients with cystic fibrosis: use of repetitive-element-sequence polymerase chain reaction. Clin Infect Dis 20: 836-841.
11. Dupon M, Winnock S, Rogues AM, Janvier G, de Barbeyrac B, Saric J 1993. Achromobacter xylosoxidans (Alcaligenes xylosoxidans subspecies xylosoxidans) bacteremia after liver transplantation. Intensive Care Med 19: 480.
12. Fraser SL, Jorgensen JH 1997. Reappraisal of the antimicrobial susceptibilities of Chryseobacterium and Flavobacterium species and methods for reliable susceptibility testing. Antimicrob Agents Chemother 41: 2738-2741.
13. Fung-Tomc J, Bush K, Minassian B, Kolek B, Flamm R, Gradelski E, Bonner D 1997. Antimicrobial activity of BMS-180680, a new catechol-containing monobactam. Antimicrob Agents Chemother 41: 1010-1016.
14. Gales AC, Jones RN, Forward KR, Linares J, Sader HS, Verhoef J 2001. Emerging importance of multidrug-resistant Acinetobacter species and Stenotrophomonas maltophilia as pathogens in seriously ill patients: geographic patterns, epidemiological features, and trends in the SENTRY Antimicrobial Surveillance Program (1997-1999). Clin Infect Dis; 32(Suppl. 2): S104-113.
15. Gungor S, Ozen M, Akinci A, Durmaz R 2003. A Chryseobacterium meningosepticum outbreak in a neonatal ward. Infect Control Hosp Epidemiol 24: 613-611.
16. Hearn YR, Gander RM 1991. Achromobacter xylosoxidans: an unusual neonatal pathogen. Am J Clin Pathol 96: 211-214.
17. Hernandez JA, Martino R, Pericas R, Sureda A, Brunet S, Domingo-Albos A1998. Achromobacter xylosoxidans bacteremia in patients with hematologic malignancies. Haematologica 83: 284-285.
18. Hsueh PR, Teng LJ, Ho SW, Hsieh WC, Luh KT 1996. Clinical and microbiological characteristics of Flavobacterium indologenes infections associated with indwelling devices. J Clin Microbiol 34: 1908-913.
19. Jones RN, Sader HS, Beach ML 2003. Contemporary in vitro spectrum of activity summary for antimicrobial agents tested against non-fermentative gram-negative bacilli (18,569 strains) isoalted in the SENTRY Antimicrobial Surveillance Program (1997-2001). Int J Antimicrob Agents 22: 551-556.
20. Kirby JT, Sader HS, Walsh TR, Jones RN 2004. Antimicrobial susceptibility and epidemiology of a worldwide collection of Chryseobacterium spp: report from the SENTRY Antimicrobial Surveillance Program (1997-2001). J Clin Microbiol 42: 445-448.
21. Klinger JD, Thomassen MJ 1985. Occurrence and antimicrobial susceptibility of gram-negative nonfermentative bacilli in cystic fibrosis patients. Diagn Microbiol Infect Dis 3: 149-158.
22. Labarca JA, Trick WE, Peterson CL, Carson LA, Holt SC, Arduino MJ, Meylan M, Mascola L, Jarvis WR 1999. A multistate nosocomial outbreak of Ralstonia pickettii colonization associated with an intrinsically contaminated respiratory care solution. Clin Infect Dis 29: 1281-1286.
23. Luk WK 1996. An outbreak of pseudobacteraemia caused by Burkholderia pickettii: the critical role of an epidemiological link. J Hosp Infect 34: 59-69.
24. Mandell WF, Garvey GJ, Neu HC 1987. Achromobacter xylosoxidans bacteremia. Rev Infect Dis 9: 1001-1005.
25. Manfredi R, Nanetti A, Ferri M, Chiodo F 1997. Bacteremia and respiratory involvement by Alcaligenes xylosoxidans in patients infected with the human immunodeficiency virus. Eur J Clin Microbiol Infect Dis 16: 933-938.
26. NCCLS-National Committee for Clinical Laboratory Standards 2003. Methods for dilution antimicrobial susceptibility test for bacteria that grow aerobically, 6th edition, Approved standard M7-A6, Wayne, PA.
27. NCCLS-National Committee for Clinical Laboratory Standards 2004. Performance standard for antimicrobial susceptibility testing. 14th Informational Supplement M100-S14. Wayne, PA.
28. Nordmann P, Poirel L, Kubina M, Casetta A, Naas T 2000. Biochemical-genetic characterization and distribution of OXA-22, a chromosomal and inducible class D beta-lactamase from Ralstonia (Pseudomonas) pickettii. Antimicrob Agents Chemother 44: 2201-2204.
29. Reverdy ME, Freney J, Fleurette J, Coulet M, Surgot M, Marmet D, Ploton C 1984. Nosocomial colonization and infection by Achromobacter xylosoxidans. J Clin Microbiol 19: 140-143.
30. Roberts LA, Collignon PJ, Cramp VB, Alexander S, McFarlane AE, Graham E, Fuller A, Sinickas V, Hellyar A 1990. An Australia-wide epidemic of Pseudomonas pickettii bacteraemia due to contamined "sterile" water for injection. Med J Aust 152: 652-655.
31. Sader HS, Jones RN 2005. Antimicrobial susceptibility of uncommonly isolated non-enteric gram-negative bacilli. Int J Antimicrob Agents 25: 95-109.
32. Saiman L, Chen Y, Tabibi S, San Gabriel P, Zhou J, Liu Z, Lai L, Whittier S 2001. Identification and antimicrobial susceptibility of Alcaligenes xylosoxidans isolated from patients with cystic fibrosis. J Clin Microbiol 39: 3942-3945.
33. Vandamme P, Bernardet JF, Segers P, Kersters K, Holmes B 1994. New perspectives in the classification of the flavobacteria: description of Chryseobacterium gen. nov., Bergeyella gen. nov., and Empedobacter nom. rev. Int J Syst Bacteriol 44: 827-831.
34. Van Pelt C, Verduin CM, Goessens WH, Vos MC, Tummler B, Segonds C, Reubsaet F, Verbrugh H, Van Belkum A 1999. Identification of Burkholderia spp. in the clinical microbiology laboratory: comparison of conventional and molecular methods. J Clin Microbiol 37: 2158-2164.
35. Visalli M, Bajaksouzian AS, Jacobs MR, Appelbaum PC 1997. Comparative activity of trovafloxacin, alone and in combination with other agents, against gram-negative nonfermentative rods. Antimicrob Agents Chemother 41: 1475-1478.
36. Yabuuchi E. Kawamura Y, Kosako Y, Ezaki T 1998. Emendation of genus Achromobacter and Achromobacter xylosoxidans (Yabuuchi and Yano) and proposal of Achromobacter ruhlandii (Packer and Vishniac) comb. nov., Achromobacter piechaudii (Kiredjian et al.) comb. nov., and Achromobacter xylosoxidans subsp. denitrificans (Ruger and Tan) comb. nov. Microbiol Immunol 42: 429-438.